Drug Trial Radar · NCT04593940
Immune Modulators for Treating COVID-19
Last checked: Nov 20, 2026Latest source record: Sep 25, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,971
Actual
Start
Oct 15, 2020
Primary completion
Jan 30, 2022
Study completion Mar 5, 2022
Sponsor
- Lead sponsor
- Daniel BenjaminAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Center for Advancing Translational Sciences (NCATS); Biomedical Advanced Research and Development Authority
- First posted
- Oct 20, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
ACTIV-1 IM is a master protocol designed to evaluate multiple investigational agents for the treatment of moderately or severely ill patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The research objectives are to evaluate each agent with respect to speed of recovery, mortality, illness severity, and hospital resource utilization. Each agent will be evaluated as add-on therapy to the standard of care (SoC) in use at the local clinics, including remdesivir (provided). The SoC may change during the course of the study based on other research findings. Comparisons of the agents among themselves is not a research objective. The study population corresponds to moderately and severely ill patients infected with the coronavirus disease 2019 (COVID-19) virus. Recruitment will target patients already hospitalized for treatment of COVID-19 infection as well as patients being treated for COVID-19 infection in Emergency Departments while waiting to be admitted to the hospital. Patients both in and out of the ICU are included in the study population.
Conditions
- Covid19
Interventions
InfliximabDrug
study drug or matching placebo
AbataceptDrug
study drug or matching placebo
RemdesivirDrug
Standard of Care
cenicriviroc (closed to enrollment as of 3-Sep-2021)Drug
study drug or matching placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Had Recovered by Day 28Time frame: Days 1-28
Locations
91 sites in 5 countries. Site status is shown where the registry gives one.
Banner University Medical Center
Phoenix, Arizona
University of Arkansas Medical Sciences
Little Rock, Arkansas
Scripps Clinical Medical Group
La Jolla, California
UCLA - Ronald Reagan Medical Center
Los Angeles, California
Riverside University
Moreno Valley, California
UC Irvine Medical Center
Orange, California
Stanford University Medical Center
Palo Alto, California
UCLA Medical Center- Santa Monica
Santa Monica, California
Medstar Washington Hospital Center
Washington D.C., District of Columbia
University of Florida-Jacksonville
Jacksonville, Florida
University of Illinois at Chicago
Chicago, Illinois
Northwestern University
Chicago, Illinois
Loyola University Medical Center
Maywood, Illinois
University of Iowa
Iowa City, Iowa
University of Kansas
Kansas City, Kansas
University of Kentucky
Lexington, Kentucky
Tulane School of Medicine
New Orleans, Louisiana
University Medical Center New Orleans
New Orleans, Louisiana
Ochsner Medical Center
New Orleans, Louisiana
Anne Arundel Medical Center
Annapolis, Maryland
Johns Hopkins Medical Center
Baltimore, Maryland
Tufts Medical Center
Boston, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts
Boston Medical Center
Boston, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts
U Mass Memorial Medical Center
Worcester, Massachusetts
U Mass University Medical Center
Worcester, Massachusetts
MidMichigan Medical Center- Gratiot
Alma, Michigan
MidMichigan Medical Center - Midland
Midland, Michigan
Mayo Clinic
Rochester, Minnesota
University of Mississippi Medical Center
Jackson, Mississippi
University of Missouri Health Care
Columbia, Missouri
Washington University School of Medicine
St Louis, Missouri
Trinitas Hospital
Elizabeth, New Jersey
Hackensack University Medical Center
Hackensack, New Jersey
Rutgers New Jersey Medical School
New Brunswick, New Jersey
NYU Brooklyn
Brooklyn, New York
University at Buffalo
Buffalo, New York
Flushing Hospital Medical Center
Flushing, New York
Jamaica Hospital Medical Center
Jamaica, New York
Showing 40 of 91 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.